Takween Advanced Industries will upgrade its production line with Sidel’s solutions that will enable the Saudi manufacturer of plastic products to increase production, reduce cost and save on energy. The move is aimed at meeting the growing market demand on milk and drinkable yogurt.
With the installation of the latest version of the SBO 10 Universal2 Ecoven on its Sidel blower, Takween will be able to reduce its use of energy by 35 percent, and produce 2,000 more bottles per hour on the same machine, which is currently producing 20,000 bottles per hour for 0.2L format. Apart from the Ecoven, Sidel will provide the air conveyors to connect to the Takween’s sleeve and bagging machines.
The project is the fourth blow molding line Sidel supplies to Takween to help them meet the growing market demands. The filling facility will receive an upgrade to the blower and will have a Sidel Ecoven installed. The Ecoven uses fewer lamps for heating the preforms, substantially reducing its energy consumption by 35 percent.
In 2013, the consumption of drinking milk products reached SR5.6 billion in Saudi Arabia, a growth of 10 percent.
Meanwhile, sales of drinkable yogurt reached SR3.7 billion, a growth of 11 percent compared to 2012. Shifting of Ramadan toward summer season is having a positive impact on sales of drinking yoghurt in the Saudi market. Pre/Pro-biotic drinking yoghurt had the strongest value growth of 21 percent.
“Our company has been closely working with Sidel over the past four years, enjoying the benefits of Sidel’s production lines, services support and solution-based approach. Our history together has been highly satisfactory for us and we are always on the lookout for upgrades that help us perform better while saving energy and costs,” said Ali A. Al-Shaier, CEO of Takween Advanced Industries.
Takween upgrades production line with Sidel solutions
Takween upgrades production line with Sidel solutions
Jameel Research project at MIT tackles antimicrobial resistance
Jameel Research, part of Abdul Latif Jameel International network, is sponsoring a research project in the Department of Biological Engineering and Institute for Medical Engineering and Science at the Massachusetts Institute of Technology, aimed at tackling the global public health crisis of antimicrobial resistance.
This ambitious, multi-disciplinary project is led by Professor James J. Collins, Termeer professor of medical engineering and science at MIT and faculty lead for life sciences at the MIT Jameel Clinic, the epicenter of artificial intelligence and health at MIT.
The project, spanning at least three years, will leverage the Collins’ lab’s cutting-edge strengths in synthetic biology and AI to create next-generation diagnostics.
The growing prevalence of antibiotic-resistant superbugs and a declining antibiotic pipeline has led to a global public health crisis. The US Centers for Disease Control and Prevention has predicted some 2 million infections and 23,000 deaths occur each year in the US alone, costing $55 billion. The World Bank predicts that up to $100 trillion of economic output may be at risk by 2050. The UK government-commissioned Review on Antimicrobial Resistance is projecting more than 10 million deaths worldwide per year by 2050 if the crisis is not addressed.
Professor Collins and his team at MIT are setting out to develop the next generation of antibacterials and rapid diagnostics to overcome AMR — using synthetic biology and advanced generative AI to deliver faster results and help control the use of antibiotics to where they can be effective.
With support from Jameel Research, the first phase of this project will develop and validate programmable antibacterials to overcome AMR in a range of bacterial pathogens. These AI-designed minibinders will be delivered by engineered microbes to neutralize key toxins and protein targets.
This directed design and engineering approach to antibiotic development technology advances a long-term vision to create programmable antibacterials to address the AMR crisis. This would then offer the potential for the more rapid development of medical countermeasures to emerging and re-emerging pathogens and a swifter response to future outbreaks and pandemics.
Mohammed Abdul Latif Jameel, KBE, chairman of Abdul Latif Jameel, said: “Antimicrobial resistance is one of the most urgent challenges we face today and addressing it will require ambitious science and sustained collaboration. We are pleased to support this new research, building on our long-standing relationship with MIT and our commitment to advancing research across the world, to strengthen global health and contribute to a more resilient future.”
“This project reflects my belief that tackling AMR requires both bold scientific ideas and a pathway to real-world impact,” Professor Collins said. “Jameel Research is keen to address this crisis by supporting innovative, translatable research at MIT.”
Jameel Research is advancing the work of pioneering pathfinders to create an extraordinary impact on a global scale.
This initial project holds the promise of rapidly developing medical countermeasures for emerging and re-emerging pathogens, offering a rapid response to future outbreaks and pandemics.
The new research project builds on the close and long-standing relationship between MIT and the Jameel family. This includes the MIT Jameel Clinic, which was co-founded in 2018 by MIT and Community Jameel, the international nonprofit organization founded by Mohammed Jameel, KBE, to advance science and learning for communities to thrive, and one of the Jameel family’s philanthropies.
